---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Average sales price and wholesale acquisition cost"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Average sales price and wholesale acquisition cost. Topics: Lorundrostat price not finalized or disclosed, November 2026; Company pricing frame: branded SGLT2 inhibitor and Entresto price points, March 2026; Price and reimbursement as competitive factors; ICER placeholder price for lorundrostat: baxdrostat wholesale acquisition cost, October 2026; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/average-sales-price-and-wholesale-acquisition-cost"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Average sales price and wholesale acquisition cost

<a id="heading-2.1.2.3"></a>

## 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

### Wholesale acquisition cost and average sales price of lorundrostat

No evidence found.

<a id="topic-2.1.2.3-2"></a>

### Lorundrostat price not finalized or disclosed, November 2026

> “As we've stated in the past, pricing is something that we'll communicate as well as our thoughts on access and gross to net sometime post approval, post launch.”
> “Part of that is price, part of that is the rebate strategy and part of it is what Eric described as the patient support program.”
> “Obviously, we haven't finalized the price yet, so that hasn't been revealed to the payer, but anticipate once we have approval, a relatively quick engagement and to start turning over some of that access in very short term.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

<a id="topic-2.1.2.3-3"></a>

### Company pricing frame: branded SGLT2 inhibitor and Entresto price points, March 2026

> “We have talked in the past, Annabel, that as a guidance or a frame for pricing, we have always directed to probably more of an SGLT2-branded price point, Entresto price point, broadly at a WAC, but have not guided as it relates to rebates.”
> “I think we continue to feel very strong about the value proposition of lorundrostat, the need specifically in the resistant hypertension population, and so we believe that both the combination of appropriate price and rebate is going to create that access.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-2.1.2.3-4"></a>

### Price and reimbursement as competitive factors

> “If we successfully obtain approval for lorundrostat or any future product candidate, we believe that the key competitive factors that will affect the success of lorundrostat will be efficacy, safety, tolerability, convenience, price, and the availability of reimbursement from government and other third-party payors relative to such competing products.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.3-5"></a>

### ICER placeholder price for lorundrostat: baxdrostat wholesale acquisition cost, October 2026

> “For baxdrostat, we used the wholesale acquisition cost (WAC) price from RedBook ($900 for 30 tablets).”
> “For lorundrostat, we used the baxdrostat WAC price as a placeholder price.”
> “At lorundrostat’s annual placeholder price of $10,950, the cumulative annual budget impact per patient was approximately $8,500 in year one and $16,300 by year five.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.1.2.3-6"></a>

### ICER health benefit price benchmark for lorundrostat, October 2026

> “The HBPB for baxdrostat is $1,400 to $2,500 per year and for lorundrostat is $760 to $1,600 per year.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
